Abstracts tagged "anti-TNF therapy"

Abstract Number: 2009 • 2019 ACR/ARP Annual Meeting
Biomarkers Identified by Serum Inflammatory Profile Analysis to Predict Biologic Treatment Response in Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Nuria Barbarroja ², Carlos Perez-Sanchez ³, Pilar Font ⁴, Alejandro Ibañez-Costa ¹, Maria Luque-Tevar ¹, Alejandra Patiño-Trives ¹, Ivan Arias de la Rosa ⁴, Maria del Carmen Abalos-Aguilera ¹, Rafaela Ortega ¹, Alejandro Escudero ⁵, Laura Pérez-Sanchez ⁶, Jerusalem Calvo-Gutierrez ¹, Rocío Segura-Ruiz ⁷, Carlos Rodriguez Escalera ⁸, Dolores Ruiz-Montesinos ⁹, Carmen Romero Barco ¹⁰, N. Mena-Vazquez ¹¹, Julia Uceda Montañez ¹², Mª Dolores Toledo Coello ¹³, M Angeles Aguirre ¹⁴ and Eduardo Collantes-Estevez ⁴, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ³Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁶MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁷Reina Sofia University Hospital/IMIBIC, Córdoba, Spain, ⁸Hospital Universitario de Jaén, Jaen, Spain, ⁹Hospital Virgen Macarena, Sevilla, ¹⁰Hospital Marítimo de Torremolinos, Málaga, Málaga, Spain, ¹¹HU Malaga., Malaga, ¹²Hospital Universitario Virgen de Valme, Sevilla, Sevilla, Spain, ¹³Hospital Universitario de Jerez de la Frontera, Cádiz, Cádiz, Spain, ¹⁴IMIBIC/Reina Sofia Hospital/University of Cordoba,, Córdoba, Spain
Background/Purpose: Biologic disease modifying antirheumatic drugs (b-DMARDs) have revolutionized the management of Rheumatoid Arthritis (RA). Despite this success, a high percentage of the patients undergoing…
Abstract Number: 936 • 2019 ACR/ARP Annual Meeting
Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes
Jonathan Kay¹, Lianne Gensler ², Atul Deodhar ³, Walter P. Maksymowych ⁴, Nigil Haroon ⁵, Simone Auteri ⁶, Natasha de Peyrecave ⁷, Thomas Kumke ⁸, Bengt Hoepken ⁹, Lars Bauer ⁹ and Martin Rudwaleit ¹⁰, ¹UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ²University San Francisco California, San Francisco, CA, ³Oregon Health & Science University, Portland, OR, ⁴University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁵Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim, Germany, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany
Background/Purpose: Patients (pts) with axial spondyloarthritis (axSpA) often experience delayed diagnosis, which can lead to treatment delay. However, there are indications that earlier treatment with…
Abstract Number: 2112 • 2019 ACR/ARP Annual Meeting
Real Life Serious Infections in Patients with Chronic Inflammatory Arthritis on Treatment with TNF Inhibitors
Alazne Ruiz ¹, Juan Ramón De Dios ², Belen Alvarez ¹, Margarida Vasques Rocha ², Claudia Stoye ², Susana Gil ¹, Orlando Pompei Fernández ² and Jaime Calvo-Alen³, ¹Hospital Universitario Araba, Vitoria, Pais Vasco, Spain, ²Araba University Hospital, Vitoria, Pais Vasco, Spain, ³Hospital Universitario Araba, Vitoria-Gasteiz, Spain
Background/Purpose: To study frequency and associated factors for serious infections in patients with inflammatory arthritis treated with TNF inhibitorsMethods: All the medical records of the…
Abstract Number: 938 • 2019 ACR/ARP Annual Meeting
TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity
Alexandre Sepriano¹, Sofia Ramiro ², Stephanie Wichuk ³, Praveena Chiowchanwisawakit ⁴, Terrie MacCosham ³, Joel Paschke ⁵, Désirée van der Heijde ¹, Robert B.M. Landewé ⁶ and Walter Maksymowych ⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ³University of Alberta, Edmonton, Canada, ⁴Mahidol University, Bangkok, Thailand, ⁵CARE Arthritis, Edmonton, Canada, ⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ⁷University of Alberta and CARE Arthritis, Edmonton, Canada
Background/Purpose: Recent observational data suggest that TNFi reduce spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) mostly by inhibiting disease activity1. Yet, resolution on the…
Abstract Number: 2117 • 2019 ACR/ARP Annual Meeting
Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis
DOROTHEE VINSON¹, LUC MOLLET-BENHAMOU ², Yannick Degboe ³, Thao Pham ⁴, Thomas BARNETCHE ⁵, Arnaud Constantin ⁶ and Adeline Ruyssen-Witrand ⁷, ¹AP-HM CHU Marseille, Marseille, France, ²CHU Toulouse, Toulouse, France, ³University of Glasgow, Glasgow, United Kingdom, ⁴Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ⁵CHU Bordeaux, Toulouse, France, ⁶CHU TOUOUSE, TOULOUSE, France, ⁷Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France
Background/Purpose: A previous meta-analysis1 showed that tapering of bDMARDs does not increase the risk of relapse in rheumatoid arthritis (RA) patients with remission or low…
Abstract Number: 29 • 2019 ACR/ARP Annual Meeting
Therapeutic Anti-TNF Biologic Agents Exhibit Functional Differences in Blocking TNF-induced Effects on Human Monocytes In Vitro
Bohdan Harvey¹ and Zehra Kaymakcalan ¹, ¹AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Therapeutic anti-TNF biologic agents can be distinct in their structure and/or in their binding to TNF. Whether these differences affect the functional properties of…
Abstract Number: 988 • 2019 ACR/ARP Annual Meeting
Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis
Bradley Hooker¹, Xiaomeng Zhang ², Todd Cole ², Ann Tovcimak ², Shaughn Bryant ³, Lucy Phillips ³, David Blanchard ², Dustin Wooten ², Qi Guo ², Melanie Ruzek ³, Adrian Hobson ³, Michael McPherson ³, Robert Stoffel ³, Wendy Waegell ³ and Yanping Luo ², ¹AbbVie, North Chicago, IL, ²AbbVie, North Chicago, ³AbbVie, Worcester
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory joint disease of autoimmune etiology. If insufficiently treated, RA leads to joint damage and irreversible disability. Although there…
Abstract Number: 2273 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Offspring According to TNFi Subtypes
Evelyne Vinet¹, Yvan St-Pierre ¹, Cristiano S. Moura ¹, Jeffrey Curtis ² and Sasha Bernatsky ³, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: TNFi subtypes have differential placental transfer, with some reaching higher fetal than maternal blood levels. Thus, certain TNFi subtypes could cause immunosuppression in the offspring.…
Abstract Number: 94 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Receptor 2 Signaling Potentiates Proliferation and Suppressive Activities of Follicular Regulatory T Cells
Shotaro kawano¹, Hiroki Mitoma ², Shoichiro Inokuchi ³, Masahiro Ayano ², Yasutaka Kimoto ⁴, Mitsuteru Akahoshi ², Yojiro Arinobu ², Koichi Akashi ², Takahiko Horiuchi ⁵ and Hiroaki Niiro ⁶, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Japan, ³Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Fukuoka, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁶Clinical Education Centre, Kyushu University Hospital, Fukuoka, Japan, Fukuoka, Japan
Background/Purpose: Tumor Necrosis Factor (TNF) α is a multifunctional cytokine with pro-inflammatory and anti-inflammatory characteristics. Regulatory T cells (Treg) express a remarkably high level of…
Abstract Number: 990 • 2019 ACR/ARP Annual Meeting
Development of a Novel Anti TNF-Steroid Antibody Drug Conjugate That Shows Promising Efficacy at Doses That Avoid Steroid Side Effects in a Mouse Model of Rheumatoid Arthritis
Wendy Waegell¹, Christian Goess ², Robert Stoffel ¹, Michael McPherson ¹, Adrian Hobson ¹, Suzanne Mathieu ², Lucy Phillips ¹ and Shaughn Bryant ¹, ¹AbbVie, Worcester, ²Abbvie bioresearch Center, Worcester, MA
Background/Purpose: TNF-inhibitors are a well established therapy for autoimmune diseases including rheumatoid arthritis, Crohn’s disease, psoriasis and ankylosing spondylitis but they have limited efficacy in…
Abstract Number: 2292 • 2019 ACR/ARP Annual Meeting
Disease Flares of Rheumatoid Arthritis During Pregnancy: What Is the Impact of Stopping bDMARDs at the Beginning of Pregnancy?
Maria Chiara Gerardi¹, Laura Andreoli ¹, Antía García-Fernández ², Chiara Bazzani ³, MATTEO FILIPPINI ³, MICAELA FREDI ¹, ROBERTO GORLA ³, Maria Grazia Lazzaroni ⁴, Cecilia Nalli ³, MARCO TAGLIETTI ⁵, SONIA ZATTI ⁶, ANDREA LOJACONO ⁶, Franco Franceschini ¹ and Angela Tincani ¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy, ²Ramon y Cajal University Hospital, Madrid, Spain, Madrid, Madrid, Spain, ³Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ⁴Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy., Brescia, Italy, ⁵[email protected], Brescia, Italy, ⁶Obstetrics and Gynaecology, Spedali Civili and University of Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: During pregnancy, patients with rheumatoid arthritis (RA) can experience flares that might influence pregnancy outcomes. We aimed at assessing disease course during pregnancy and…
Abstract Number: 377 • 2019 ACR/ARP Annual Meeting
Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition
Matthew Baker¹, Khushboo Sheth ¹, Julia Simard ², Stanford Shoor ¹ and Mark Genovese ³, ¹Stanford University, Palo Alto, CA, ²Stanford University School of Medicine, Palo Alto, CA, ³Stanford University, Stanford, CA
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by the presence of noncaseating granulomas. When it affects the myocardium, it can result in electrical conduction…
Abstract Number: 1242 • 2019 ACR/ARP Annual Meeting
Impact of Smoking Status on Remission in Hidradenitis Suppurativa
Amil Agarwal ¹, Marissa Mangini ¹, Derek Jones ¹, Catherine Hood ¹, Richard Amdur ¹ and Victoria Shanmugam², ¹The George Washington University School of Medicine and Health Sciences, Washington, DC, ²George Washington University, Georgetown, DC
Background/Purpose: Hidradenitis Suppurativa (HS) is an inflammatory disease of the apocrine sweat glands characterized by recurrent abscessing inflammation. The molecular drivers of HS are poorly…
Abstract Number: 2297 • 2019 ACR/ARP Annual Meeting
Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate’s Immune System
Yiyi Luo ¹, Andrea Pluma ², Raul Castellanos-Moreira³, Estefania Moreno ⁴, Nuria Baños ⁵, Sebastian DC Rodriguez-Garcia ⁶, Angela Deyà-Martínez ¹, Ana Pilar Garcia-Garcia ¹, Mireia Torres ⁷, Dolors Grados ⁸, Manel Casellas ⁹, Manel Juan ¹, Ana Esteve-Sole ¹ and Laia Alsina ¹⁰, ¹Immunology Department. Center for Biomedical Diagnosis. Hospital Clínic of Barcelona IDIBAPS. Barcelona University. Barcelona. Functional unit of Clinical Immunology HSJD-HCP.Universidad de Barcelona. Pediatric Investigation Institute SJD, Barcelona, Spain, ²Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁴Rheumatology Department. Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain, ⁵Matern-Infantile Department, Hospital Clínic of Barcelona. Barcelona. Spain, Barcelona, Spain, ⁶Arthritis Unit. Rheumatology Department. Hospital Clinic of Barcelona. Barcelona. Spain, Barcelona, Spain, ⁷Neonatology Department. Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain, ⁸Hospital d'Igualada, Barcelona, ⁹Hospital Universitari Vall d'Hebron, Barcelona, ¹⁰Hospital Sant Joan de Déu, Barcelona, Spain
Background/Purpose: Up to half of pregnant patients with rheumatic diseases experience disease activity which can increase the risk of pregnancy complications and poor disease outcomes. Treatment…
Abstract Number: 419 • 2019 ACR/ARP Annual Meeting
Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study
Panagiotis Athanassiou ¹, Ioannis Kallitsakis ², Gkikas Katsifis ³, Anastasios Kotrotsios ⁴, Georgios Vosvotekas ⁵, Panagiotis Georgiou ⁶, Andreas Bounas ⁷, Yiannis Haratsis ⁸, Evangelia Petrikkou ⁸ and Dimitrios Vassilopoulos⁹, ¹General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, ²Private Practice, Chania, Greece, ³Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, ⁴Private Practice, Karditsa, Greece, ⁵Euromedica General Clinic of Thessaloniki, Rheumatology Clinic, Thessaloniki, Greece, ⁶General Hospital of Patras “Agios Andreas”, Patras, Greece, ⁷Olympion therapeutirion, Patras, Greece, ⁸Merck Sharp & Dohme Pharmaceutical, Industrial and Commercial S.A, Medical Affairs, Athens, Greece, ⁹2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece
Background/Purpose: There are limited real life data regarding the effect of golimumab on work productivity and activity impairment in rheumatic diseases. The aim of our…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].